Panitumumab (Vectibix)

J.J. Gemmete and S.K. Mukherji

*AJNR Am J Neuroradiol* 2011, 32 (6) 1002-1003
doi: https://doi.org/10.3174/ajnr.A2601
http://www.ajnr.org/content/32/6/1002

This information is current as of September 15, 2023.
Panitumumab is a human monoclonal antibody antagonist specific to the EGFR (also known as EGF receptor, c-erbB-1, and HER1 in humans). It is indicated as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Drug approval by the FDA is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival with panitumumab. Panitumumab is manufactured by Amgen (Thousand Oaks, California) and is marketed as Vectibix.

**Mechanism of Action**

EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including HER2, HER3, and HER4. EGFR is constitutively expressed in normal epithelial tissues, including the skin and hair follicles. EGFR is overexpressed in certain human cancers, including colon and rectal cancer. Panitumumab works by binding to the extracellular domain of the EGFR preventing its activation. This results in halting of the cascade of intracellular signals dependent on this receptor (Fig 1).

**Clinical Indication**

The FDA approved panitumumab for the first time in September 2006, for the treatment of EGFR-expressing metastatic colorectal cancer with disease progression despite prior treatment. Panitumumab was approved by the European Medicines Agency in 2007 and by Health Canada in 2008 for the treatment of refractory EGFR-expressing metastatic colorectal cancer with nonmutated (wild-type) KRAS. Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.

**Administration and Side Effects**

Panitumumab is administered at 6 mg/kg every 14 days as an intravenous infusion for 60 minutes (≤1000 mg) or 90 minutes (>1000 mg). Panitumumab administered as a single agent exhibits nonlinear pharmacokinetics. The elimination half-life is approximately 7.5 days (range, 3.6–10.9 days). No formal pharmacokinetic studies of panitumumab have been conducted in patients with renal or hepatic impairment, to our knowledge.

The most common adverse reactions (≥20%) are skin toxicities (ie, erythema, dermatitis acneiform, pruritus, exfoliation, rash, and fissures), paronychia, hypomagnesemia, fatigue, abdominal pain, nausea, diarrhea, and constipation. The most serious adverse events with the administration of panitumumab include pulmonary fibrosis, pulmonary embolism, and severe dermatologic toxicity. Electrolyte levels should be monitored along with clinical signs of dermatologic and ocular toxicity.

**Economic Issues**

Like other genetically engineered monoclonal antibodies, panitumumab is quite expensive, and the costs can vary widely from country to country. Panitumumab costs approximately $3000 per treatment in the United States based on an average healthy male weight of 70 kg.

**References**

Fig 1. Schematic illustration of the proposed mechanism of panitumumab. Panitumumab is a monoclonal antibody that binds to the extracellular portion of the EGFR preventing dimerization and the cascade that leads to the expression of growth factors. (Illustration courtesy of Carolyn Nowak.)